Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Protagonist Therapeutics’ drug rusfertide reduced the need for phlebotomies as a way to treat the rare blood cancer polycythemia vera. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology. The post Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages appeared first on MedCity News.

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass. -- Protagonist Therapeutics, Inc. (“Protagonist”) ( NASDAQ:PTGX) and Takeda ( TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s e…

Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV

No new safety concerns emerged in the 20-week extension of the phase 3 VERIFY study. Medscape Medical News Source link : https://www.medscape.com/viewarticle/hematocrit-phlebotomy-benefits-seen-rusfertide-pv-2025a1000y84?src=rss Author : Publish date : 2025-12-07 19:08:00 Copyright for syndicated content belongs to the linked Source. The post Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV first appeared on News Health.

Rusfertide Provides Durable Hematocrit Control in Polycythemia Vera | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Rusfertide shows sustained hematocrit control and high phlebotomy ineligibility in polycythemia vera patients, demonstrating safety and efficacy through 52 weeks.

52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV

Rusfertide shows promise in maintaining hematocrit control and improving quality of life for polycythemia vera patients, reducing phlebotomy needs significantly.

Takeda (NYSE: TAK) sees 61.9% durable rusfertide response in 52-week PV VERIFY study

52-week VERIFY results show 61.9% of PV patients on rusfertide avoided phlebotomy eligibility, while 4-year THRIVE data cut annual phlebotomies 13-fold.